Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0N0QC
|
|||
| Former ID |
DNCL002147
|
|||
| Drug Name |
GV1001
|
|||
| Synonyms |
GV1001
Click to Show/Hide
|
|||
| Drug Type |
Vaccine
|
|||
| Indication | Pancreatic cancer [ICD-11: 2C10] | Phase 3 | [1] | |
| Company |
KAEL-GemVax
|
|||
| PubChem Substance ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Telomerase reverse transcriptase (TERT) | Target Info | . | [2] |
| NetPath Pathway | IL2 Signaling Pathway | |||
| Pathway Interaction Database | Validated targets of C-MYC transcriptional activation | |||
| Regulation of Telomerase | ||||
| IL2 signaling events mediated by PI3K | ||||
| Regulation of nuclear beta catenin signaling and target gene transcription | ||||
| HIF-1-alpha transcription factor network | ||||
| Reactome | Formation of the beta-catenin:TCF transactivating complex | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT01579188) Study of the Telomerase Vaccine GV1001 to Treat Patients With Inoperable Stage III Non-small Cell Lung Cancer. U.S. National Institutes of Health. | |||
| REF 2 | Telomerase peptide vaccination of patients with non-resectable pancreatic cancer: A dose escalating phase I/II study. Br J Cancer. 2006 Dec 4;95(11):1474-82. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.